University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "GASTROINTESTINAL"



Treatment trials which apply specifically to your search:


0C-10-8

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients.

Treatment:
Chemotherapy: Systemic

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-12-4

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Multi-Center, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies.

Treatment:
Chemotherapy: Systemic

0C-12-6

Trial Leaders:
Anthony El-Khoueiry

A Phase IB Ascending Multi-Arm, Dose Escalation Study of BMS-906024 Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-4

Trial Leaders:
Heinz Josef Lenz

A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Treatment:
Chemotherapy: Systemic

0C-13-5

Trial Leaders:
Anthony El-Khoueiry

A Phase I and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients with BRAF v600x Mutations and Renal or Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-13-8

Trial Leaders:
Heinz Josef Lenz

A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies

Treatment:
Chemotherapy: Systemic

0C-14-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-11

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 In Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC), Melanoma, Clear Cell Renal Cell Carcinoma (RCC) or Squamous Cell Head And Neck Cancer (SCCHN)

Treatment:
Chemotherapy: Systemic

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-14-3

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-5

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Dose Escalation Study of PF-06664178 In Patients with Locally Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-6

Trial Leaders:
David Quinn

A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

Treatment:
Immunotherapy

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
Tanya Dorff

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-11-12

Trial Leaders:
Kevin Kelly

Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination with the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.

Treatment:
Chemotherapy: Systemic

0S-13-4

Trial Leaders:
James Hu

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) vs. Bleomycin, Etoposide and Cisplatin (BEP) for Patients with Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

0S-14-5

Trial Leaders:
David Quinn

A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients with Relapsed, Refractory, Incurable Teratoma with Recent Progression

Treatment:
Chemotherapy: Systemic

0S-14-6

Trial Leaders:
Kevin Kelly

Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects with Refractory or Relapsed Lymphoma or Multiple Myeloma

Treatment:
Chemotherapy: Systemic

10M-12-2

Trial Leaders:
Michael Wong

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIb-IV Melanoma

Treatment:
Chemotherapy: Systemic

10M-14-4

Trial Leaders:
Michael Wong

Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells INGM-CSF (DC-TC) Vs. Autologous Peripheral Blood Mononuclear Cells In GM-CSF (MC) for the Treatment of Patients with Metastatic Melanoma

Treatment:
Other

11S-15-1

Trial Leaders:
James Hu

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

Treatment:
Biological Response Modifier

13NHL-12-1

Trial Leaders:
Ann Mohrbacher

A Phase I Study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Treatment:
Immunotherapy

13NHL-14-3

Trial Leaders:
Anil Tulpule

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of lenalidomide (CC-5013) plus R-Chop Chemotherapy (R2-Chop) versus Placebo plus R-Chop Chemotherapy in Subjects with Previously Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma

Treatment:
Chemotherapy: Systemic

16M-13-2

Trial Leaders:
Ann Mohrbacher

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Treatment:
Chemotherapy: Systemic

1B-10-3

Trial Leaders:
Julie Lang

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Treatment:
Chemotherapy: Systemic

1B-11-5

Trial Leaders:
Agustin Garcia

A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response.

Treatment:
Other

1B-12-1

Trial Leaders:
Christina M. Dieli-Conwright

Combined Exercise Program for Early Breast Cancer Survivors.

Treatment:
(No treatments specified)

1B-13-10

Trial Leaders:
Darcy Spicer

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer. (The “METRIC” Study)

Treatment:
Chemotherapy: Systemic

1B-13-11

Trial Leaders:
Christy Russell

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician’s Choice In Previously-Treated, HER2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment:
Chemotherapy: Systemic

1B-14-1

Trial Leaders:
Christy Russell

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)

Treatment:
Chemotherapy: Systemic

1B-14-3

Trial Leaders:
Christy Russell

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-14-4

Trial Leaders:
Darcy Spicer

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-14-7

Trial Leaders:
Heather R. Macdonald

Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women

Treatment:
Other

1B-14-8

Trial Leaders:
Darcy Spicer

A Phase 2, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer (CO-3810-025)

Treatment:
Chemotherapy: Systemic

2N-12-5

Trial Leaders:
Barbara Gitlitz

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination with the MEK Inhibitor Trametinib in Subjects with BRAF V600E Mutation-Positive Metastatic (Stage IV) Non-Small Cell Lung Cancer.

Treatment:
Chemotherapy: Systemic

2N-13-4

Trial Leaders:
Barbara Gitlitz

A Randomized Phase II Trial of Cytotoxic Chemotherapy with or without Epigenetic Priming in Patients with Advanced Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-13-6

Trial Leaders:
Barbara Gitlitz

A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat Prior to Nivolumab versus Nivolumab Alone in Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-14-3

Trial Leaders:
Eugene Chung

Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-Small Cell Lung Cancer

Treatment:
Radiation: External
Surgery

2N-14-4

Trial Leaders:
Jorge Nieva

TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Biological Response Modifier

2O-14-1

Trial Leaders:
Barbara Gitlitz

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Treatment:
Chemotherapy: Systemic

3BD-14-1

Trial Leaders:
Jaques Van Dam

Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma

Treatment:
Chemotherapy: Systemic
Other

3C-13-6

Trial Leaders:
Jane Figueiredo

A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers.

Treatment:
(No treatments specified)

3C-14-1

Trial Leaders:
Heinz Josef Lenz

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Treatment:
Chemotherapy: Systemic

3C-14-2

Trial Leaders:
Heinz Josef Lenz

Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies

Treatment:
Chemotherapy: Systemic

3C-14-4

Trial Leaders:
Heinz Josef Lenz

A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic

3C-14-5

Trial Leaders:
Heinz Josef Lenz

A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.

Treatment:
Anti-Angiogenesis

3C-15-1

Trial Leaders:
Heinz Josef Lenz

An Open-Label Expanded Access Study of Tas-102 in Patients with Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Treatment:
Chemotherapy: Systemic

3GB-14-1

Trial Leaders:
Anthony El-Khoueiry

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy

Treatment:
Chemotherapy: Systemic

3GB-15-1

Trial Leaders:
Anthony El-Khoueiry

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

Treatment:
Chemotherapy: Systemic

3L-12-3

Trial Leaders:
Anthony El-Khoueiry

A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis.

Treatment:
Immunotherapy

3L-13-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Treatment:
Chemotherapy: Systemic

3L-13-4

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Cancer

Treatment:
Chemotherapy: Systemic

3P-12-1

Trial Leaders:
Heinz Josef Lenz

Phase IB Multi-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Anti-Neoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ß-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX).

Treatment:
Chemotherapy: Systemic

3P-13-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

3P-13-3

Trial Leaders:
Heinz Josef Lenz

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment:
Chemotherapy: Systemic

3P-14-2

Trial Leaders:
Anthony El-Khoueiry

A Phase 3, Multicenter, Open-Label, Randomized Study of Nab-Paclitaxel plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Treatment:
Chemotherapy: Systemic

3R-12-2

Trial Leaders:
Afsaneh Barzi

Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
Immunomodulator

4B-06-1

Trial Leaders:
David Quinn

Ph II-75, A Phase I/II Study of E7389 Halichondrin B Analog (NSC #707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency.

Treatment:
Chemotherapy: Systemic

4B-13-2

Trial Leaders:
David Quinn

A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-containing Regimen Hoosier Oncology Group GU12-160; The Borealis-2 Clinical Trial

Treatment:
Chemotherapy: Systemic

4B-14-3

Trial Leaders:
David Quinn

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer

Treatment:
Chemotherapy: Systemic

4B-14-5

Trial Leaders:
Sarmad Sadeghi

PHII-130 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder

Treatment:
Chemotherapy: Systemic

4K-12-2

Trial Leaders:
David Quinn

Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma.

Treatment:
Biological Response Modifier
Immunotherapy

4K-13-1

Trial Leaders:
David Quinn

A Randomized Phase II Study of AMG386 With or Without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
Immunotherapy

4K-13-3

Trial Leaders:
David Quinn

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib vs. Placebo In Subjects At High Risk Of Recurrent RCC

Treatment:
Chemotherapy: Systemic

4K-14-1

Trial Leaders:
David Quinn

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Treatment:
Chemotherapy: Systemic

4P-06-3

Trial Leaders:
Jacek Pinski

A Phase I/II Trial of Adjuvant Post-Prostatectomy 3-D Conformal Radiation Therapy, Hormonal Therapy, and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer.

Treatment:
Chemotherapy: Systemic
Hormone
Radiation: External

4P-12-6

Trial Leaders:
David Quinn

PhII-123, A Randomized Gene Fusion Stratified Phase II Trial of Abiraterone With or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer.

Treatment:
Chemotherapy: Systemic

4P-13-2

Trial Leaders:
E. Todd Schroeder

Exercise and Protein Supplementation for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy.

Treatment:
Other

4P-13-8

Trial Leaders:
David Quinn

A randomized open-label phase IIa study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in subjects with castration-resistant prostate cancer who have bone metastases

Treatment:
Chemotherapy: Systemic
Radiation: External

4P-14-1

Trial Leaders:
Mitchell Gross

Phase 2 Trial of Phenelzine in Non-Metastatic Recurrent Prostate Cancer

Treatment:
Chemotherapy: Systemic

4P-14-2

Trial Leaders:
Jacek Pinski

A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Treatment:
Chemotherapy: Systemic

4P-14-4

Trial Leaders:
Tanya Dorff

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Treatment:
Chemotherapy: Systemic

4P-14-8

Trial Leaders:
Leslie Ballas

Phase I dose-escalation study of SBRT for adjuvant/salvage radiotherapy in prostate cancer

Treatment:
Radiation: Other

5C-11-2

Trial Leaders:
Lynda Roman

Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer.

Treatment:
Chemotherapy: Systemic

5GYN-13-1

Trial Leaders:
Annie Yessaian

The MILO Study (MEK Inhibitor in Low-Grade Serous Ovarian Cancer): A Multi-National, Randomized, Open-Label Phase III Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Treatment:
Chemotherapy: Systemic

5U-13-1

Trial Leaders:
Koji Matsuo

PhII-129 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer

Treatment:
Chemotherapy: Systemic

6G-11-2

Trial Leaders:
Naveed Wagle

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma.

Treatment:
Vaccine

6G-12-2

Trial Leaders:
Naveed Wagle

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma.

Treatment:
Anti-Angiogenesis
Vaccine

6G-13-1

Trial Leaders:
Thomas Chen

A Prospective, Non-Randomized, Concurrent Control, Open Label, Post-Approval Study Of NovoTTF-100A In Recurrent GBM Patients

Treatment:
Chemotherapy: Systemic
Other

7H-13-2

Trial Leaders:
Barbara Gitlitz

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Chemotherapy: Systemic
Immunotherapy

7H-14-2

Trial Leaders:
Jorge Nieva

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Treatment:
Immunotherapy

9L-11-8

Trial Leaders:
Ann Mohrbacher

HLA-Mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High-Risk Acute Myeloid Leukemia.

Treatment:
Chemotherapy: Systemic
Other

9L-12-5

Trial Leaders:
Akil Merchant

A Phase IB/II Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low-Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Treatment:
Chemotherapy: Systemic

9L-13-1

Trial Leaders:
Casey O'Connell

Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN)

Treatment:
(No treatments specified)

9L-13-2

Trial Leaders:
Casey O'Connell

Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia

Treatment:
Chemotherapy: Systemic

9L-14-1

Trial Leaders:
Kevin Kelly

A multi-center, open-label, phase 1/1b Study of escalating doses of RO5503781 Administered orally as 1) a single Agent, 2) in combination with cytarabine, Or 3) with cytarabine and anthracycline In patients with acute myelogenous Leukemia (AML)

Treatment:
Chemotherapy: Systemic

9L-14-3

Trial Leaders:
Kevin Kelly

A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif®) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Treatment:
Chemotherapy: Systemic

9L-14-4

Trial Leaders:
Casey O'Connell

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Treatment:
Chemotherapy: Systemic

9L-14-5

Trial Leaders:
Casey O'Connell

A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Treatment:
Chemotherapy: Systemic

9L-15-1

Trial Leaders:
Casey O'Connell

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Treatment:
Chemotherapy: Systemic

CTSU-A081105

Trial Leaders:
Barbara Gitlitz

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

CTSU-E1411

Trial Leaders:
Anil Tulpule

Intergroup Randomized Phase II Four Arm Study In Patients =/>60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab + Bendamustine Followed By Rituximab Consolidation (RB-R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R); Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR); or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV-LR).

Treatment:
Chemotherapy: Systemic
Immunomodulator
Immunotherapy

CTSU-E2810

Trial Leaders:
David Quinn

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

Treatment:
Anti-Angiogenesis

CTSU-E4512

Trial Leaders:
Barbara Gitlitz

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment:
Chemotherapy: Systemic

CTSU/A031201

Trial Leaders:
Amir Goldkorn

Phase III Trial of Enzalutamide (NSC # 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Treatment:
Chemotherapy: Systemic

CTSU/AEWS1031

Trial Leaders:
James Hu

A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

Treatment:
Chemotherapy: Systemic
Radiation: External
Surgery

ctsu/CALGB-A011202

Trial Leaders:
Heather R. Macdonald

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

CTSU/CALGB-A021202

Trial Leaders:
Syma Iqbal

Prospective Randomized Phase II Trial Of Pazopanib (NSC # 737754, IND 75648) Versus Placebo In Patients With Progressive Carcinoid Tumors

Treatment:
Chemotherapy: Systemic

CTSU/CALGB/SWOG-C80702

Trial Leaders:
Heinz Josef Lenz

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

Treatment:
Chemotherapy: Systemic

CTSU/COG-NRG ARST1321

Trial Leaders:
James Hu

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib

Treatment:
Radiation: External

CTSU/E2211

Trial Leaders:
Syma Iqbal

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors.

Treatment:
Chemotherapy: Systemic

CTSU/E7208

Trial Leaders:
Heinz Josef Lenz

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Treatment:
Anti-Angiogenesis

CTSU/NCCTG-N107C

Trial Leaders:
Eric Chang

A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.

Treatment:
Radiation: External

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Eugene Chung

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

CTSU/RTOG-1112

Trial Leaders:
Anthony El-Khoueiry

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Treatment:
Chemotherapy: Systemic
Radiation: External

ctsu/RTOG0848

Trial Leaders:
Syma Iqbal

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Treatment:
Chemotherapy: Systemic
Radiation: External

GOG-0225

Trial Leaders:
Huyen Q. Pham

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?

Treatment:
(No treatments specified)

GOG-9929

Trial Leaders:
Huyen Q. Pham

A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA with Positive Lymph Nodes.

Treatment:
Chemotherapy: Systemic
Immunotherapy
Radiation: External

NC-HEM-14-1

Trial Leaders:
Ilene Weitz

Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.

Treatment:
Other

NC-HEM-14-2

Trial Leaders:
Howard Liebman

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

Treatment:
Chemotherapy: Systemic

NC-HEM-14-4

Trial Leaders:
Howard Liebman

Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open-label Study with Multiple and (for non-responders) Escalating Subcutaneous Doses of BI 655064 Once a week in Patients with Chronic Primary Immune Thrombocytopenic Purpura

Treatment:
Other

NC-HEM-14-5

Trial Leaders:
Ilene Weitz

An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Treatment:
(No treatments specified)

NRG-BR001

Trial Leaders:
Eugene Chung

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Treatment:
Radiation: External

RTOG-0815

Trial Leaders:
Leslie Ballas

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.

Treatment:
Hormone
Radiation: External

RTOG-0924

Trial Leaders:
Leslie Ballas

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy In Unfavorable Intermediate Or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Treatment:
Radiation: External

RTOG-1010

Trial Leaders:
Heinz Josef Lenz

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma.

Treatment:
Chemotherapy: Systemic
Immunomodulator
Radiation: External
Surgery

RTOG-1203

Trial Leaders:
Suisui Song

A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

Treatment:
Radiation: External

SWOG-S0820

Trial Leaders:
Syma Iqbal

A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

Treatment:
Other

SWOG-S0905

Trial Leaders:
Barbara Gitlitz

A Phase I/Randomized Phase II Study of Cediranib (NSC #732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma.

Treatment:
Anti-Angiogenesis

SWOG-S0931

Trial Leaders:
Tanya Dorff

EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.

Treatment:
Anti-Angiogenesis

SWOG-S1007

Trial Leaders:
Darcy Spicer

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1011

Trial Leaders:
Siamak Daneshmand

A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.

Treatment:
Surgery

SWOG-S1200

Trial Leaders:
Christy Russell

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer.

Treatment:
Other

SWOG-S1206

Trial Leaders:
Barbara Gitlitz

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Treatment:
(No treatments specified)

SWOG-S1207

Trial Leaders:
Darcy Spicer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1216

Trial Leaders:
David Quinn

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1221

Trial Leaders:
Anthony El-Khoueiry

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer.

Treatment:
Chemotherapy: Systemic

SWOG-S1304

Trial Leaders:
Kevin Kelly

A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease.

Treatment:
Chemotherapy: Systemic

SWOG-S1313

Trial Leaders:
Syma Iqbal

A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.

Treatment:
Chemotherapy: Systemic

SWOG-S1314

Trial Leaders:
Siamak Daneshmand

A Randomized Phase II Study of Co-Expression Extrapolation (Coxen) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Treatment:
Chemotherapy: Systemic

SWOG-S1406

Trial Leaders:
Heinz Josef Lenz

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic

Phase I trials for all solid tumors:


0C-10-8

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients.

Treatment:
Chemotherapy: Systemic

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-12-6

Trial Leaders:
Anthony El-Khoueiry

A Phase IB Ascending Multi-Arm, Dose Escalation Study of BMS-906024 Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-14-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-3

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-5

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Dose Escalation Study of PF-06664178 In Patients with Locally Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-6

Trial Leaders:
David Quinn

A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

Treatment:
Immunotherapy

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

SWOG-S1221

Trial Leaders:
Anthony El-Khoueiry

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer.

Treatment:
Chemotherapy: Systemic

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-00-15

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer.


0S-00-16

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer.


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-08-15

Trial Leaders:
Charite Ricker

Cancer Genetics Family Registry - Molecular Genetics Studies of Cancer Patients and Their Relatives.


0S-08-5

Trial Leaders:
Darcy Spicer

Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project.


0S-10-1

Trial Leaders:
Florence Wong

A Survey of Complementary and Alternative Medicine (CAM) Use and Interest to Participate in CAM Research Studies in a Comprehensive Cancer Center.


0S-11-3

Trial Leaders:
Charite Ricker

Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-11-9

Trial Leaders:
Michael Wong

Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-13-1

Trial Leaders:
Gregory Idos

USC Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing


0S-99-10

Trial Leaders:
Heinz Josef Lenz

Blood Collection in Patients with GI Cancer.


11S-14-1

Trial Leaders:
Mittul Gulati

Real-time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Quantitative Imaging Techniques for Early Therapy Response Assessment in Sarcomas


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-4

Trial Leaders:
Marisa Perdomo

Screening for Musculoskeletal Impairments and Quality of Life in Individuals Post-Treatment for Breast Cancer.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-12-9

Trial Leaders:
Darcy Spicer

An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-13-8

Trial Leaders:
Linda Hovanessian

Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer.


1B-14-6

Trial Leaders:
Anna Wu

Changes in Intestinal Microbiota in Association with Chemotherapy Treatment


2L-10-1

Trial Leaders:
Barbara Gitlitz

Addario Lung Cancer Medical Institute (ALCMI) Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.


2L-14-1

Trial Leaders:
Barbara Gitlitz

Genomics of Young Lung Cancer Study


2N-12-7

Trial Leaders:
Daniel Oh

DNA Methylation Markers for Detecting Cancer Cells in Malignant Pleural Effusion.


2O-13-1

Trial Leaders:
Barbara Gitlitz

Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer


3C-13-2

Trial Leaders:
Afsaneh Barzi

A Pilot Study of Monitoring Metastatic Colorectal Cancers with Liquid Biopsies.


3G-07-2

Trial Leaders:
Heinz Josef Lenz

Early Onset and Familial Gastric Cancer Registry.


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


3G-07-4

Trial Leaders:
Heinz Josef Lenz

Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers.


4B-13-1

Trial Leaders:
Siamak Daneshmand

4B-13-1 Cysview® Blue Light Cystoscopy Registry


4B-13-4

Trial Leaders:
Siamak Daneshmand

Evaluation of the UroVysion™ Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade Ta-T1 and CIS Urothelial Carcinoma of the Bladder


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


4K-13-2

Trial Leaders:
Vinay Duddalwar

CT Metrology: Quantitative Imaging Metrics with Advanced Visualization Tools for Cancer Imaging


4P-01-2

Trial Leaders:
Eila Skinner

Prostate Cancer Prostatectomy Data and Specimen Collection Project.


4P-11-4

Trial Leaders:
Mitchell Gross

Multi-Dimensional Assessment of Circulating Tumor Cells in Patients Treated For Metastatic Prostate Cancer.


4P-12-3

Trial Leaders:
Alan Epstein

MDSC Clinical Assay for Cancer Detection and Monitoring in Prostate Cancer.


4P-14-6

Trial Leaders:
Mitchell Gross

Assessment of Novel Biomarkers in Patients with Metastatic Castration Resistant Prostate Cancer


5GYN-10-3

Trial Leaders:
Lynda Roman

Banking Tissues from Normal and Disease-Related Gynecologic Surgeries.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


9L-10-3

Trial Leaders:
Preet Chaudhary

Comprehensive Hematology Tissue Repository (BANK).


ACRIN 6685

Trial Leaders:
John L. Go

A Multi-Center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients.


ACRIN 6701

Trial Leaders:
Suzanne Palmer

Repeatability Assessment of Quantitative DCE-MRI and DWI: A Multicenter Study of Functional Imaging Standardization in the Prostate


CTSU-A151216

Trial Leaders:
Barbara Gitlitz

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)


CTSU/A011104/ACRIN6694

Trial Leaders:
Pulin A. Sheth

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer


NC-HEM-06-5

Trial Leaders:
Anil Tulpule

Retrospective Clinipathologic Analysis of HIV-Associated Hodgkin’s Disease.


NC-HEM-12-1

Trial Leaders:
Anil Tulpule

Inhibition of proteasomal degradation of Nrf2 to augment antioxidant responses in sickle cell anemia


SWOG-S1013

Trial Leaders:
Heinz Josef Lenz

A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities.